Resmed (RMD) is a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders such as sleep apnoea.
RMD operates in over 65 countries through 16 direct offices and a network of distributors, including Australia, France, Germany, New Zealand, Singapore, the UK and the United States.
Last week, RMD announced a 1H11 net profit of US$115.2 million, up 30.7% from a year earlier.
Revenue increased 12.6% to US$359,953, driven by growth in flow generators and masks sales.
Resmed said it expects growth of all of its products to continue to benefit from the growth in the sleep-disordered breathing market.
RMD lost 2.1% last week, underperforming the share market, which gained 0.4%.